SMARCB1 Deficiency in Tumors Confers Vulnerability to H3K27 Demethylase Inhibitors via Autophagy Disruption.
SMARCB1-deficient tumors are highly sensitive to H3K27 demethylase inhibitors, with GSK-J4 suppressing tumor growth in patient-derived models.
- Why it matters: Understanding vulnerabilities in SWI/SNF complex-deficient cancers can lead to targeted therapies for aggressive tumors like malignant rhabdoid tumors, which lack effective treatments.
- What they did: The study examined SMARCB1-deficient cells, including pediatric MRTs, revealing their heightened sensitivity to GSK-J4 due to altered H3K27 modifications, elevated autophagy, and stress responses.
- The result: GSK-J4 effectively inhibits tumor growth in models, highlighting a specific dependency on H3K27 demethylase activity in SMARCB1-mutant cancers and offering a promising therapeutic avenue.